With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
Many molecularly distinct subgroups emerged from a meta-analysis bringing together more than 1,000 high-grade glioma or diffuse intrinsic pontine glioma cases.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
Even in schizophrenia cases lacking intellectual disability, investigators found that rare mutations in genes normally resistant to loss-of-function changes were enriched.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
Researchers are developing new algorithms and using machine-learning techniques that can integrate vast amounts of cancer omics data to identify potential therapies.
Shared gastric adenocarcinoma tumor features seem to span geography and ethnicity, despite shifts in the proportion of tumors from different molecular subtypes.
